Bomi Italia : 2-11-2016 BOMI ITALIA S.P.A. - BOMI GROUP ANNOUNCE ITS RETURN TO THE CHINESE MARKET

Bomi Italia S.p.A.

- PRESS RELEASE -

Bomi Group announces its return to the Chinese market Vaprio d'Adda, 2 November 2016 - Bomi Italia S.p.A. ("Bomi" or the "Company" or "Issuer"), the holding company of Bomi Group, a leader in biomedical logistics and management of advanced technology health products, listed on the AIM Italia / Alternative Capital Market multilateral trading system, announces that it acquired today 100% of the share capital of Biomedical Distribution Asia Holding Limited, with headquarters in Hong Kong, as well as its subsidiary, Bomi Logistics Jiangsu Co. Ltd, with headquarters in Suzhou, China, specialised in managing the storage and transport of biomedical products, both founded by Bomi Group, then later sold.

The transaction is part of a more general strategy of directly controlling sales activities in individual countries, allowing the Group to re-enter the Asian market by having a direct commercial relationship with the customer Qiagen, one of the top companies in the diagnostics market. China clearly represents a strategic market for the pharmaceutical and medical devices sector, in terms of potential and growth.

Although China is an important global exporter of medical devices in only certain sectors, it is the third largest importer worldwide of medical devices, and, in particular, it is the second biggest global importer in the field of biomedical and electromedical diagnostics.

There are various factors that have had an impact on this trend and on growth forecasts. First and foremost, the Chinese population is the largest in the world, and lifestyle changes, environmental conditions, the aging population and higher disposable income for the middle class have driven healthcare spending up from 5% to 7% of the country's GDP.

The transaction envisages a payment of Euro 475,000, of which Euro 50,000 will be paid in the twelve (12) months following the closing, at established revenue conditions.

Marco Ruini, Vice Chairman and Chief Executive Officer of Bomi Italia S.p.A., stated, "This transaction represents an important step for the growth of Bomi Group in a strategic market like China, where the biomedical sector was determined to be one of seven fundamental areas in China's 12th five-year plan."

Bomi Italia S.p.A. is the holding company of Bomi Group, a leader in biomedical logistics and management of advanced technology health products. The Company is among the first to have obtained the "Elite" certificate from Borsa Italiana.

Bomi Group's activities are focused in the segment of integrated logistics, offering a wide range of logistical services in outsourcing to healthcare companies, managing, specifically, medical devices, pharmaceuticals, products for in vitro diagnostics, reagents and implantable products.

The Bomi Group has a portfolio of more than 100 customers, including the most important global players in the healthcare sector (such as leading pharmaceutical companies and manufacturers of medical devices), as well as small and medium-sized companies in the biomedical, diagnostics and biotech sector at a global level. Currently, the Group has approximately 1,000 employees and a presence, through subsidiaries and investee companies, in Europe, South America, China and the United States. Its services are also provided through strategic alliances with local partners.

ISIN Code for ordinary shares: IT0005108748 - Ordinary shares ticker: BOMI

ISIN Code for convertible bonds: IT0005114480 - Convertible bonds ticker: BOMI20

For more information

Bomi Italia S.p.A. ●	Banca Popolare di Vicenza S.p.A. ●
Investor Relator	Nominated Adviser
tel: [phone]	tel: [phone]
email: [e-mail]	email: [e-mail]